All In Biotech

Drug Trial Radar · NCT07932314

Prognostic Value of Oxygen-15 Water PET in Coronary Artery Disease

Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR Trial

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

40,000

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2036

Study completion Dec 2036

Sponsor

Lead sponsor
Vastra Gotaland RegionGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Sahlgrenska University Hospital; Gothia Forum - Center for Clinical Trial
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the prognostic value of quantitative myocardial perfusion imaging using oxygen-15 water positron emission tomography in patients with clinically suspected or known coronary artery disease (main basket), and explores temporal changes in myocardial perfusion related to disease progression, underlying pathophysiological processes, or treatment-related effects (additional baskets).

Conditions

  • Coronary Artery Disease
  • Microvascular Coronary Artery Disease
  • Microvascular Coronary Dysfunction

Interventions

  • Oxygen-15 WaterDrug

    Oxygen-15 water enables absolute quantification of myocardial blood flow at rest and during pharmacological stress using PET. In the main basket, participants will undergo a single quantitative myocardial perfusion imaging examination using oxygen-15 water PET at rest and during pharmacological stress (adenosine or regadenoson). In the additional baskets, the same examination will be performed twice, at baseline and at follow-up. In all baskets, blood samples will be collected when feasible and stored in a biobank for future research.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prognostic Thresholds of Stress Myocardial Blood Flow for Predicting MACE-1 (Main Basket)Time frame: 2 and 5 years after the PET examination
  2. Prognostic Thresholds of Rest Myocardial Blood Flow for Predicting MACE-1 (Main Basket)Time frame: 2 and 5 years after the PET examination
  3. Prognostic Thresholds of Myocardial Flow Reserve for Predicting MACE-1 (Main Basket)Time frame: 2 and 5 years after the PET examination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Clinical Physiology, Sahlgrenska University Hospital

    Gothenburg, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.